Sort
23,748 grants matching “melanoma”
Risk Factors for Nevus Development in Children
$543,676Lori A Crane · University Of Colorado Denver · R01 · FY2012 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$543,527James R. Heath · Institute For Systems Biology · U01 · FY2017 · CA
DEVELOPMENT OF DIAGNOSTIC TOOLS FOR METASTATIC MELANOMA VIA IMAGING OF HEPARANASE ACTIVITY
$543,330University Of Florida · · FY2017 · Department of the Army
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS
$543,088David Reardon · Duke University · P50 · FY2010 · NS
Non-coding RNA regulation of Myeloid Cells
$543,051Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2025 · CA
Tissue Resident memory T cell responses to cancer
$543,000Mary J Turk · Dartmouth College · R01 · FY2024 · CA
Nitric Oxide as a Modifier of Oxidative Stress
$542,980David Wink · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
Immune Therapy for Brain Metastasis
$542,905Lucia Beatrice Jilaveanu · Yale University · R01 · FY2024 · CA
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2025 · AI
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2024 · AI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
$542,889Jun Wang · New York University School Of Medicine · R37 · FY2024 · CA
Regulatory Network Differences/Diverse Tumor Subtypes/Design Combinatorial Therap
$542,875Chris Sander · Sloan-Kettering Inst Can Research · U54 · FY2014 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$542,768Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2017 · CA
Engineering ferritin degrader-encapsulated platelets for post-surgical TNBC treatment
$542,721Quanyin Hu · University Of Wisconsin-Madison · R01 · FY2025 · EB
Engineering ferritin degrader-encapsulated platelets for post-surgical TNBC treatment
$542,721Quanyin Hu · University Of Wisconsin-Madison · R01 · FY2024 · EB
DEVELOPMENTAL FUNDS (Core 002)
$542,437Nancy E Davidson · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · CA
Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis
$542,407Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Mechanism of Activity of Lonidamine
$542,325Jerry D Glickson · University Of Pennsylvania · R01 · FY2016 · CA
Mechanism of Activity of Lonidamine
$542,325Jerry D Glickson · University Of Pennsylvania · R01 · FY2017 · CA
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma
$542,305Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Advancing T cell Therapy for Ovarian Cancer
$542,075George Coukos · Fox Chase Cancer Center · P50 · FY2010 · CA
Manipulating normal estrogen physiology as a therapeutic approach in cancer
$542,002Donald P McDonnell · Duke University · R01 · FY2025 · CA
Harnessing NKT Cell Activation by Glycolipids
$541,909Amy R. Howell · University Of Connecticut Storrs · R01 · FY2019 · GM
Integrated Discovery Pipeline for Tumor Neoantigens
$541,899Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2020 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$541,844Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA